Real Cases of Rare Diseases - Primary Hyperoxaluria Type 1 (PH1): Expert Guidance on Recognition and Management

Released On
September 30, 2021

Expires On
September 30, 2022

Media Type

Completion Time
60 minutes

Nephrology, Pediatrics, Urology

Rare Diseases, Nephrology, Urology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and Enquiring Minds, LLC.

This activity is supported by an independent education grant from Alnylam Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of physicians, registered nurses and other healthcare professionals who specialize or have an interest in rare diseases, nephrology, urology, genetics and PH1.

Program Overview

This interactive case-based activity requires clinicians to make real-world decisions as they optimize diagnostic and therapeutic strategies for patients with suspected PH1.

Throughout the activity practitioners will have the opportunity to immediately implement expert guidance and evaluate performance while addressing challenging questions about the latest clinical data and evidence-based recommendations.

Topics addressed include:

  • Differential diagnosis, including criteria and tools
  • Available and evolving therapeutic options
  • Tailoring treatment plans
  • Identifying and addressing obstacles to diagnosis and management


Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review key clinical characteristics of PH1 and recommend strategies for its early and accurate diagnosis
  • Evaluate and integrate the latest clinical evidence for available and investigational treatments when tailoring treatment plans for patients with PH1
  • Summarize challenges related to the diagnosis and management of PH1 and implement strategies to address those challenges




David S. Goldfarb, MD, FASN

Professor of Medicine and Physiology
Clinical Chief of Nephrology
Director, Kidney Stone Prevention Program
NYU Langone Health


Physician Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Enquiring Minds, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team..


Physician Credit Designation

Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

David S. Goldfarb MD

  • Receipt of Intellectual Property Rights/Patent Holder: Dr. Arnie’s Inc.
  • Consulting Fees (e.g., advisory boards): Alnylam, Synlogic, Allena, AstraZeneca, Travere
  • Contracted Research: Dicerna, Akebia
  • Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Dr. Arnie’s Inc.


The PIM planners and others have nothing to disclose. The Enquiring Minds, LLC planners and others have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CE credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant


Course Viewing Requirements

Supported Browsers:
Internet Explorer 11, Microsoft Edge (latest version)
Google Chrome for Windows or Mac OS (latest version)
Mozilla Firefox for Windows or Mac OS (latest version)
Safari (latest version)

Supported Phones & Tablets:
Google Chrome (latest version) in Android OS 6 or later
Safari in Apple iOS 12 or later, Google Chrome (latest version) in AppleiOS 12 or later

Required Browser Settings
JavaScript: Must be enabled
Font Downloads: Must be enabled
No Compatibility View when using Internet Explorer

The following screen readers are supported:
NVDA (latest version)
JAWS (latest version)
VoiceOver (Mac, Apple iOS, Apple iPadOS)
TalkBack (latest version – Android OS)

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information

For CME questions please contact: